NCT04837001: An ongoing trial by Faraday Pharmaceuticals, Inc.
This trial is ongoing. It must report results 8 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04837001 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous FDY 5301 in Patients With an Anterior ST-Elevation Myocardial Infarction |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 2, 2022 |
| Completion date | Sept. 3, 2025 |
| Required reporting date | Sept. 3, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |